Characterization of Monocyte-Derived Dendritic Cells from Immunosuppressed Renal Transplant Recipients with and without Squamous Cell Carcinomas

Authors

  • L. F. Sandvik,

    1. Department of Dermatology, Haukeland University Hospital, Bergen, Norway
    2. Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
    Search for more papers by this author
  • R. Volchenkov,

    1. Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
    Search for more papers by this author
  • R. Jonsson,

    1. Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
    Search for more papers by this author
  • S. Appel

    Corresponding author
    1. Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
    • Correspondence to: S. Appel, Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Laboratory Building, 5th Floor West, N-5021 Bergen, Norway. E-mail: silke.appel@k2.uib.no

    Search for more papers by this author

Abstract

Renal transplant recipients (RTR) have a high risk of tumour development, especially cutaneous squamous cell carcinomas (SCC), due to long-term immunosuppressive therapy. RTR may develop multiple lesions over short time periods, and these are often more aggressive with a higher risk of local recurrence and metastasis resulting in increased morbidity and mortality in these patients. Therefore, we took the first step towards evaluating the possibility of generating a therapeutic vaccine based on monocyte-derived dendritic cells (moDC) for these patients. We analysed the phenotype and cytokine/chemokine profile of moDC from long-term immunosuppressed RTR with and without previous SCC. The number of peripheral blood mononuclear cells (PBMC) isolated per ml blood as well as the efficiency of generating moDC from peripheral blood mononuclear cells (PBMC) was similar in patients and immunocompetent controls. Phenotype and cytokine/chemokine profile of the moDC from immunosuppressed patients were similar to those from immunocompetent controls, making moDC-based immunotherapy a potential future treatment option for RTR with multiple SCC.

Ancillary